A recent analysis that sequenced both primary BC and BrMs tissue found that ESR1 mutations were present in 28.1% of BrMs, despite the associated loss of ER expression by immunohistochemistry.31 Our findings add to the growing body of literature as per above that ESR1 mutations are a hallmark of endocrine therapy-resistant breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.